| 摘要 |
THE INVENTION RELATES TO COMPOUNDS OF THE FORMULA I WHEREIN: A IS AN OPTIONALLY SUBSTITUTED RING SYSTEM, PROVIDED THAT THE -CH(R3)N(R2)B-R1 AND -OR4 GROUPS ARE POSITIONED IN A 1,2 RELATIONSHIP TO ONE ANOTHER ON RING CARBON ATOMS AND THE RING ATOM POSITIONED ORTHO TO THE OR4 LINKING GROUP (AND THEREFORE IN THE 3-POSITION RELATIVE TO THE -CHR3NR2- LINKING GROUP) IS NOT SUBSTITUTED; B IS AN OPTIONALLY SUBSTITUTED RING SYSTEM: R1 IS POSITIONED ON RING B IN A 1,3 OR 1,4 RELATIONSHIP WITH THE -CH(R3)N(R2)-LINKING GROUP AND IS AS DEFINED IN THE SPECIFICATION. R2 IS HYDROGEN, C1-6ALKYL, OPTIONALLY SUBSTITUTED BY HYDROXY, CYANO OR TRIFLUOROMETHYL, C2-6ALKENYL (PROVIDED THE DOUBLE BOND IS NOT IN THE 1-POSITION), C2-6ALKYNYL (PROVIDED THE TRIPLE BOND IS NOT IN THE 1-POSITION), PHENYLC1-3ALKYL OR PYRIDYIC1-3ALKYL; R3 IS HYDROGEN, METHYL OR ETHYL; R4 IS OPTIONALLY.SUBSTITUTED: C1-6ALKYL, C3-7CYCLOALKYIC1-3ALKYL OR C3-7CYCLOALKYL; AND N OXIDES OF-NR WHERE CHEMICALLY POSSIBLE; AND S-OXIDES OF SULPHUR CONTAINING RINGS WHERE CHEMICALLY POSSIBLE; AND PHARMACEUTICALLY ACCEPTABLE SALTS AND IN VIVO HYDROLYSABLE ESTERS AND AMI DES THEREOF. PROCESSES FOR THEIR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
|
